Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Protein Kinases and Phosphatases

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...

Protein Kinases and Phosphatases

Protein Kinases and Phosphatases

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Drugs that Destabilize Microtubules

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...

Covalently Linked Protein Regulators

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Discovery of CNS Penetrant SOS1 Inhibitors for the Treatment of KRAS-Dependent Cancers.

Journal of medicinal chemistry·2026

Same author

An Inducible BRCA1 Expression System with In Vivo Applicability Uncovers Activity of the Combination of ATR and PARP Inhibitors to Overcome Therapy Resistance.

Cancers·2026

Same author

HMMR has oncoprotein-like properties in neuroblastoma cells and high HMMR expression has independent prognostic potential in neuroblastomas.

Scientific reports·2025

Same author

Integrin-Targeted, Short Interfering RNA Nanocomplexes for Neuroblastoma Tumor-Specific Delivery Achieve <i>MYCN</i> Silencing with Improved Survival.

Advanced functional materials·2022

Same author

The cytotoxic action of BCI is not dependent on its stated DUSP1 or DUSP6 targets in neuroblastoma cells.

FEBS open bio·2022

Same author

Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape.

Cancers·2022

Search research articles

Related Experiment Video

Updated: Feb 16, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Vanadium Compounds as PTP Inhibitors.

Elsa Irving¹, Andrew W Stoker²

¹Developmental Biology and Cancer Programme, UCL Great Ormond Street Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK. elsa.irving.15@ucl.ac.uk.

Molecules (Basel, Switzerland)

|December 20, 2017

Summary

This summary is machine-generated.

Vanadium compounds show potential as protein tyrosine phosphatase (PTP) inhibitors for treating diabetes and cancer. Further research is needed to improve their delivery and reduce toxicity for therapeutic use.

Keywords:

BMOV PTP cancer diabetes oxidovanadium oxovanadium protein tyrosine phosphatases vanadate vanadium

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

Related Experiment Videos

Last Updated: Feb 16, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

Area of Science:

Biochemistry
Medicinal Chemistry
Pharmacology

Background:

Phosphotyrosine signaling is crucial, regulated by protein tyrosine kinases (PTKs) and phosphatases (PTPs).
Vanadium derivatives are explored as potential inhibitors of PTPs and as metallotherapeutics.

Purpose of the Study:

To review the potential of vanadium derivatives as PTP inhibitors and metallotherapeutics.
To discuss recent developments in the biological and biochemical actions of complex vanadium compounds.
To examine pre-clinical anti-diabetic and anti-cancer studies.

Main Methods:

Review of literature on vanadium compounds, PTP inhibition, and pre-clinical studies.
Discussion of the mechanisms of PTP inhibition by vanadate and its derivatives.
Analysis of biological and biochemical effects of complex vanadium compounds.

Main Results:

Vanadate (V oxidized state) acts as a pan-inhibitor of PTPs.
Complex vanadium derivatives, including decavanadate and oxidovanadium compounds with organic ligands, show pre-clinical efficacy in anti-diabetic and anti-cancer contexts.
PTP inhibition is implicated, but other biochemical effects and off-target toxicities are observed.

Conclusions:

Vanadium compounds hold therapeutic promise, but clinical trial progress is hindered by toxicity concerns.
Improved delivery and tissue targeting are crucial to minimize off-target toxicities and realize the full therapeutic potential of vanadium compounds.
Continued interest in vanadium-based metallotherapeutics persists despite current challenges.